The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics Authors: Ian A. Cree, Mark J. Arends, Joseph D. Khoury, Erika R. E. Denton, Anthony J. Gill, Alexander J. Lazar, Ian M. Frayling, Stefan M. Pfister, Mark A. Rubin, Katia R. M. Leite, Raymond Dalgleish, Elspeth A. Bruford, Sharon E. Plon, Ada Hamosh, Michael Francis Walsh, Gabrielle Goldman‐Lévy, Harshima Wijesinghe, William D. Foulkes, Dilani Lokuhetty Published: 2026 ABSTRACT ABSTRACTThe WHO Classification of Tumours is used widely by histopathologists and other disciplines as it provides an internationally agreed taxonomy of neoplastic disorders. Now published online and in print, it has often included genetic tumour syndromes (GTS) relevant to particular organs, as suggested by the editorial board. This highlighted the lack of a systematic classification of GTS, providing international standards for their diagnosis and a basis for research. The need for this was established by a series of meetings, leading to the adoption of a hierarchical classification of GTS based on the cellular mechanism affected, the molecular pathway involved, the clinical syndrome and the gene defects present. The major cellular mechanisms affected were identified as: growth factor receptors and related pathways; oxidative stress response and metabolism; cell cycle and apoptosis; DNA repair and genomic stability; telomere maintenance; epigenetic drivers and chromatin; RNA regulation and protein regulation. Assembly of the classification emphasised current gaps in knowledge, together with the need for further research. The new classification highlights the relationships between some genetic syndromes and provides an internationally agreed framework for the incorporation of new information as it becomes available. Introduction The diagnosis of patients and their families with genetic tumour predisposition syndromes has assumed increasing clinical importance, as it germline findings now directly influence surveillance, therapeutic decision‐making and risk assessment across multiple organ systems. The World Health Organization (WHO) Classification of Tumours, provides the internationally accepted framework for tumour taxonomy, underpinning diagnostic practice worldwide and evolving through successive evidence‐based editions [1, 2, 3, 4, 5] on a 5‐to‐6‐year cycle between editions, now completing the fifth edition WHO Classification of Tumours (WCT5) [2, 3, 4, 5]. Despite this progress, genetic tumour syndromes (GTS) have historically been incorporated in a fragmented manner, typically as appendices to WHO organ‐specific classifications. This approach obscures biological relationships, limits cross‐disciplinary integration given that many disorders impact multiple tumour types and fails to reflect the mechanistic basis of tumour predisposition. At the same time, gene‐centric catalogues, while valuable, do not adequately capture the shared pathways and cellular processes through which diverse variants converge to drive neoplasia. To address this gap, we developed a hierarchical classification of GTS based on four linked levels: cellular mechanism, molecular pathway, clinical syndrome and genetic change (Figure 1). This structure reflects the biological architecture of tumour predisposition, allowing syndromes to be grouped by shared mechanisms while preserving clinical and genetic specificity. The resulting framework provides a simplified but extensible ontology that supports both diagnostic application and the systematic incorporation of emerging knowledge. An example of the hierarchical classification for GTS for RAD51‐related cancer predisposition showing the cellular mechanism, pathway, syndrome and genes involved. This new (WHO) Classification of GTS, the last volume of the fifth edition, was developed through multidisciplinary collaboration, drawing on expertise in pathology, clinical genetics, oncology and molecular biology, and informed by bibliometric analysis and international consensus discussions. It represents a first step towards a unified, mechanism‐based taxonomy of GTS within the WHO system. Terminology After some discussion we agreed that the name, ‘genetic tumour syndrome’ as a short form for genetic tumour predisposition syndrome was the best description of these disorders. The collective term ‘genetic’ was preferred over ‘familial’ or ‘hereditary’, so that the classification could encompass those syndromes which often have a post‐zygotic causation. There was considerable debate over the use of the term ‘germline’ or ‘constitutional’, with the decision going to the former term as translation of ‘constitutional’ can have problems in countries where it can be confused with consanguinity. As ‘germline’ is also more commonly used within the published literature, this was therefore preferred. Table 1 outlines common terms and definitions used throughout the volume. TABLE 1Glossary of terms commonly used in the description of genetic tumour predisposition syndromes.TermDefinitionAlleleDifferent versions of the same gene or variant.ConstitutionalA sequence variant present in all the body's cells, including the germ cells, that can therefore be passed on to offspring.GeneThe basic unit of inheritance, containing the information encoding specific peptides/proteins or RNAs.GermlineIn this context, used as synonym for ‘constitutional’, though usually regarded as defining the germ cells—sperm and oocytes that pass on genetic material to offspring.Mosaic(ism)A genetic change present in some but not all cells in the body, caused by post‐zygotic mutation and resulting in mutiple genotypes within the individual affected.PenetranceThe age‐dependent cumulative incidence of a trait (phenotype) that is associated with the variant (or allele) of a gene (the genotype).PathogenicA genomic variant is called pathogenic if there is a direct and strong link between the change and a particular condition or syndrome.Post‐zygoticA change in the genome that is acquired during the lifespan of an individual, instead of being inherited (see mosaicism).SequenceThe sequence of nucleotides in DNA or RNA, or amino acids in protein.SomaticThe cells in the body other than sperm and oocytes (germ cells) and their gonadal progenitors.SyndromeA set of medical signs and symptoms (and pathological abnormalities) which are correlated with each other and often associated with a particular disease or disorder.TaxonomyAn ordered arrangement of groups or categories, used to indicate relationships.VariantA genetic variant is a permanent change in the DNA sequence. Not all variants are pathogenic. Glossary of terms commonly used in the description of genetic tumour predisposition syndromes. There are few issues around the accurate and standardised description of genes and DNA sequence variance, which has been expertly curated by the HUGO Gene Nomenclature Committee (HGNC) [6, 7] and the Human Genome Variation Society (HGVS) for many years [8, 9, 10, 11]. However, there are several instances where colloquial shorthand is often used in medical practice rather than the more accurate (and often longer) correct scientific notation. The classification uses the scientific terms, and includes the colloquial terms where these will benefit understanding. One example is in the reporting of sequence variants in the histone H3.3 genes [12], in which the numbering based on immunohistochemistry (the more frequent use in practice) and on the DNA sequence differs, leading to possible confusion. Syndromes, by contrast, are given names according to their published names and common usage. We have listed these by chromosomal location and gene in Table 2. There is a move towards a dyadic disease nomenclature including the gene symbol for GTS, but this is by no means ubiquitous (Table 2) [13]. The syndrome we call hereditary gastric and breast cancer syndrome (HGBCS) in the classification is an autosomal dominant GTS with inactivating constitutional CDH1 or CTNNA1 sequence variants, which has also been called hereditary diffuse gastric cancer (HDGC) syndrome; hereditary lobular breast cancer (HLBC); diffuse gastric and lobular breast cancer syndrome; diffuse gastric cancer syndrome/lobular breast cancer syndrome (DGCS/LBCS); CDH1‐related tumour susceptibility syndrome or cadherin‐related tumour susceptibility syndrome. This is largely historical, but a clear cause of confusion. In line with our practice in naming tumours, we have listed alternative terminology as ‘acceptable’, or ‘not recommended’, which we hope will go some way to solving these issues. TABLE 2Tumour susceptibility genes included within the classification are here listed by chromosomal location with their corresponding HGNC gene symbol, ID and gene name.HGNC gene symbolChromosomal locationHGNC gene IDHGNC gene nameAssociated syndrome(s) Chromosome 1 PIK3CD 1p36.22HGNC:8977Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit deltaActivated phosphatidylinositol‐3‐OH kinase δ syndrome MAD2L2 1p36.22HGNC:6764Mitotic arrest deficient 2 like 2Fanconi anaemia (FANC‐V) SDHB 1p36.13HGNC:10681Succinate dehydrogenase complex iron sulfur subunit BSDH‐deficient tumour syndrome—hereditary phaeochromocytoma‐paraganglioma syndromes MUTYH 1p34.1HGNC:7527mutY DNA glycosylase MUTYH‐associated polyposis NRAS 1p13.2HGNC:7989NRAS proto‐oncogene, GTPaseNoonan syndrome; Schimmelpenning–Feuerstein–Mims SDHC 1q23.3HGNC:10682Succinate dehydrogenase complex subunit CSDH‐deficient tumour syndrome—Hereditary phaeochromocytoma‐paraganglioma syndromes GPR161 1q24.2HGNC:23694G protein‐coupled receptor 161Naevoid basal cell carcinoma syndrome—Gorlin syndrome CDC73 1q31.2HGNC:16783Cell division cycle 73Hyperparathyroidism jaw tumour syndrome UBE2T 1q32.1HGNC:25009Ubiquitin conjugating enzyme E2 TFanconi anaemia (FANC‐T) FH 1q43HGNC:3700Fumarate hydrataseHereditary leiomyomatosis and renal cell carcinoma syndrome Chromosome 2 ALK 2p23.2‐p23.1HGNC:427ALK receptor tyrosine kinaseHereditary neuroblastoma SOS1 2p22.1HGNC:11187SOS Ras/Rac guanine nucleotide exchange factor 1Noonan syndrome MSH2 2p21‐p16.3HGNC:7325mutS homolog 2Lynch syndrome; Muir–Torre syndrome; constitutional mismatch repair deficiency (CMMRD) syndrome MSH6 2p16.3HGNC:7329mutS homolog 6Lynch syndrome; Muir–Torre syndrome; constitutional mismatch repair deficiency (CMMRD) syndrome BUB1 2q13HGNC:1148BUB1 mitotic checkpoint serine/threonine kinaseMosaic variegated aneuploidy ANAPC1 2q13HGNC:19988Anaphase promoting complex subunit 1Rothmund–Thomson syndrome type 1 ERCC3 2q14.3HGNC:3435ERCC excision repair 3, TFIIH core complex helicase subunitXeroderma pigmentosum PDE11A 2q31.2HGNC:8773Phosphodiesterase 11ACarney complex IDH1 2q34HGNC:5382Isocitrate dehydrogenase (NADP(+)) 1Enchondromatosis Chromosome 3 FANCD2 3p25.3HGNC:3585FA complementation group D2Fanconi anaemia (FANC‐D2) VHL 3p25.3HGNC:12687von Hippel–Lindau tumor suppressorVon Hippel–Lindau syndrome XPC 3p25.1HGNC:12816XPC complex subunit, DNA damage recognition and repair factorXeroderma pigmentosum MLH1 3p22.2HGNC:7127mutL homolog 1Lynch syndrome; Muir–Torre syndrome; constitutional mismatch repair deficiency (CMMRD) syndrome BAP1 3p21.1HGNC:950BRCA1 associated deubiquitinase 1 BAP1‐related tumour predisposition syndrome GATA2 3q21.3HGNC:4171GATA binding protein 2Haematolymphoid genetic disorder MBD4 3q21.3HGNC:6919Methyl‐CpG binding domain 4, DNA glycosylaseMBD4‐associated neoplasia syndrome TERC 3q26.2HGNC:11727Telomerase RNA componentDyskeratosis congenita PIK3CA 3q26.32HGNC:8975Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alphaPROS syndrome Chromosome 4 PHOX2B 4p13HGNC:9143Paired like homeobox 2BHereditary neuroblastoma PDGFRA 4q12HGNC:8803Platelet‐derived growth factor receptor alphaSDH‐deficient tumour syndrome—hereditary phaeochromocytoma‐paraganglioma syndromes; Gastrointestinal stromal tumour predisposition syndrome KIT 4q12HGNC:6342KIT proto‐oncogene, receptor tyrosine kinaseGastrointestinal stromal tumour predisposition syndrome Chromosome 5 SDHA 5p15.33HGNC:10680Succinate dehydrogenase complex flavoprotein subunit ASDH‐deficient tumour syndrome—hereditary phaeochromocytoma‐paraganglioma syndromes TRIP13 5p15.33HGNC:12307Thyroid hormone receptor interactor 13Mosaic variegated aneuploidy TERT 5p15.33HGNC:11730Telomerase reverse transcriptaseDyskeratosis congenita; POT1 and shelterin‐related tumour predisposition syndrome DROSHA 5p13.3HGNC:17904drosha ribonuclease IIIMicroRNA processor tumour predisposition syndromes PDE8B 5q13.3HGNC:8794Phosphodiesterase 8BCarney complex APC 5q22.2HGNC:583APC regulator of Wnt signaling pathwayFamilial adenomatous polyposis; gastric adenocarcinoma and proximal polyposis of stomach—GAPPS CTNNA1 5q31.2HGNC:2509Catenin alpha 1Hereditary gastric and breast cancer syndrome DDX41 5q35.3HGNC:18674DEAD‐box helicase 41 DDX41‐related haematologic tumour predisposition syndrome Chromosome 6 FANCE 6p21.31HGNC:3586FA complementation group EFanconi anaemia (FANC‐E) POLH 6p21.1HGNC:9181DNA polymerase etaXeroderma pigmentosum TBXT 6q27HGNC:11515T‐box transcription factor TFamilial chordoma Chromosome 7 PMS2 7p22.1HGNC:9122PMS1 homolog 2, mismatch repair system componentLynch syndrome; Muir–Torre syndrome; constitutional mismatch repair deficiency (CMMRD) syndrome IKZF1 7p12.2HGNC:13176IKAROS family zinc finger 1Haematolymphoid genetic disorder SAMD9 7q21.2HGNC:1348Sterile alpha motif domain containing 9 SAMD9‐related haematologic tumour predisposition syndrome SAMD9L 7q21.2HGNC:1349Sterile alpha motif domain containing 9 like SAMD9L‐related haematologic tumour predisposition syndrome MET 7q31.2HGNC:7029MET proto‐oncogene, receptor tyrosine kinaseHereditary papillary renal carcinoma POT1 7q31.33HGNC:17284Protection of telomeres 1 POT1 and shelterin‐related tumour predisposition syndrome SMO 7q32.1HGNC:11119Smoothened, frizzled class receptor SMO‐related Curry–Jones syndrome EZH2 7q36.1HGNC:3527Enhancer of zeste 2 polycomb repressive complex 2 subunitWeaver syndrome XRCC2 7q36.1HGNC:12829X‐ray repair cross complementing 2 RAD51‐related cancer predisposition syndrome (Fanconi Anemia, FANC‐U) Chromosome 8 WRN 8p12HGNC:12791WRN RecQ like helicaseWerner syndrome FGFR1 8p11.23HGNC:3688Fibroblast growth factor receptor 1Encephalocraniocutaneous lipomatosis NBN 8q21.3HGNC:7652NibrinNijmegen breakage syndrome EXT1 8q24.11HGNC:3512Exostosin glycosyltransferase 1Osteochondromatosis MAFA 8q24.3HGNC:23145MAF bZIP transcription factor A MAFA‐related familial insulinomatosis RECQL4 8q24.3HGNC:9949RecQ like helicase 4Rothmund–Thomson syndrome type 2 Chromosome 9 CDKN2A 9p21.3HGNC:1787Cyclin dependent kinase inhibitor 2A CDKN2A‐related tumour predisposition syndrome FANCG 9p13.3HGNC:3588FA complementation group GFanconi anaemia (FANC‐G) PAX5 9p13.2HGNC:8619Paired box 5Haematolymphoid genetic disorder GNAQ 9q21.2HGNC:4390G protein subunit alpha qSturge–Weber syndrome FANCC 9q22.32HGNC:3584FA complementation group CFanconi anaemia (FANC‐C) PTCH1 9q22.32HGNC:9585Patched 1Naevoid basal cell carcinoma syndrome—Gorlin syndrome XPA 9q22.33HGNC:12814XPA, DNA damage recognition and repair factorXeroderma pigmentosum ELP1 9q31.3HGNC:5959Elongator acetyltransferase complex subunit 1 ELP1‐related medulloblastoma predisposition syndrome TSC1 9q34.13HGNC:12362TSC complex subunit 1Tuberous sclerosis Chromosome 10 RET 10q11.21HGNC:9967ret proto‐oncogeneMultiple endocrine neoplasia type 2 BMPR1A 10q23.2HGNC:1076Bone morphogenetic protein receptor type 1AJuvenile polyposis syndrome PTEN 10q23.31HGNC:9588Phosphatase and tensin homologue PTEN hamartoma tumour syndrome FAS 10q23.31HGNC:11920Fas cell surface death receptorAutoimmune lymphoproliferative syndrome SUFU 10q24.32HGNC:16466SUFU negative regulator of hedgehog signallingNaevoid basal cell carcinoma syndrome—Gorlin syndrome BUB3 10q26.13HGNC:1151BUB3 mitotic checkpoint proteinMosaic variegated aneuploidy Chromosome 11 HRAS 11p15.5HGNC:5173HRas proto‐oncogene, GTPaseCostello syndrome; Schimmelpenning–Feuerstein–Mims IGF2 11p15.5HGNC:5466Insulin like growth factor 2Beckwith–Wiedemann spectrum CDKN1C 11p15.4HGNC:1786Cyclin‐dependent kinase inhibitor 1CBeckwith–Wiedemann spectrum FANCF 11p14.3HGNC:3587FA complementation group FFanconi anaemia (FANC‐F) WT1 11p13HGNC:12796WT1 transcription factor WT1‐related tumour predisposition syndrome; WAGR syndrome EXT2 11p11.2HGNC:3513Exostosin glycosyltransferase 2Osteochondromatosis DDB2 11p11.2HGNC:2718Damage specific DNA binding protein 2Xeroderma pigmentosum SDHAF2 11q12.2HGNC:26034Succinate dehydrogenase complex assembly factor 2SDH‐deficient tumour syndrome—hereditary phaeochromocytoma‐paraganglioma syndromes MEN1 11q13.1HGNC:7010Menin 1Multiple endocrine neoplasia type 1 SF3B2 11q13.1HGNC:10769Splicing factor 3b subunit 2Goldenhar syndrome CEP57 11q21HGNC:30794Centrosomal protein 57Mosaic variegated aneuploidy ATM 11q22.3HGNC:795ATM serine/threonine kinaseAtaxia‐telangiectasia syndrome SDHD 11q23.1HGNC:10683Succinate dehydrogenase complex subunit DSDH‐deficient tumour syndrome—hereditary phaeochromocytoma‐paraganglioma syndromes CBL 11q23.3HGNC:1541Cbl proto‐oncogeneNoonan syndrome Chromosome 12 ETV6 12p13.2HGNC:3495ETS variant transcription factor 6Haematolymphoid genetic disorder CDKN1B 12p13.1HGNC:1785Cyclin‐dependent kinase inhibitor 1BMultiple endocrine neoplasia type 4 KRAS 12p12.1HGNC:6407KRas proto‐oncogene, GTPaseNoonan syndrome; Schimmelpenning‐Feuerstein‐Mims CDK4 12q14.1HGNC:1773Cyclin dependent kinase 4 CDK4‐related melanoma predisposition syndrome PTPN11 12q24.13HGNC:9644Protein tyrosine phosphatase non‐receptor type 11Noonan syndrome POLE 12q24.33HGNC:9177DNA polymerase epsilon, catalytic subunitPolymerase proofreading‐associated polyposis Chromosome 13 BRCA2 13q13.1HGNC:1101BRCA2 DNA repair associated1 BRCA‐related cancer predisposition syndrome; Fanconi anaemia (FANC‐D1) RB1 13q14.2HGNC:9884RB transcriptional corepressor 1Retinoblastoma syndrome ERCC5 13q33.1HGNC:3437ERCC excision repair 5, endonucleaseXeroderma pigmentosum Chromosome 14 TINF2 14q12HGNC:11824TERF1 interacting nuclear factor 2Dyskeratosis congenita MAX 14q23.3HGNC:6913MYC‐associated transcriptional regulator XMultiple endocrine neoplasia type 5 DICER1 14q32.13HGNC:17098dicer 1, ribonuclease III DICER1‐related tumour predisposition Chromosome 15 GREM1 15q13.3HGNC:2001gremlin 1, DAN family BMP antagonistHereditary mixed polyposis syndrome BUB1B 15q15.1HGNC:1149BUB1 mitotic checkpoint serine/threonine kinase BMosaic variegated aneuploidy FAH 15q25.1HGNC:3579Fumarylacetoacetate hydrolaseHereditary tyrosinaemia type 1 FANCI 15q26.1HGNC:25568FA complementation group IFanconi anaemia (FANC‐I) IDH2 15q26.1HGNC:5383Isocitrate dehydrogenase (NADP(+)) 2Enchondromatosis BLM 15q26.1HGNC:1058BLM RecQ like helicaseBloom syndrome Chromosome 16 NTHL1 16p13.3HGNC:8028 nth like DNA glycosylase 1 NTHL1‐related tumour syndrome TSC2 16p13.3HGNC:12363TSC complex subunit 2Tuberous sclerosis SLX4 16p13.3HGNC:23845SLX4 structure‐specific endonuclease subunitFanconi anaemia (FANC‐P) ERCC4 16p13.12HGNC:3436ERCC excision repair 4, endonuclease catalytic subunitXeroderma pigmentosum PALB2 16p12.2HGNC:26144Partner and localiser of BRCA2 PALB2‐related cancer predisposition syndrome CYLD 16q12.1HGNC:2584CYLD lysine 63 deubiquitinaseBrooke–Spiegler syndrome ACD 16q22.1HGNC:25070ACD shelterin complex subunit and telomerase recruitment factor POT1 and shelterin‐related tumour predisposition syndrome; dyskeratosis congenita CDH1 16q22.1HGNC:1748Cadherin 1Hereditary gastric and breast cancer syndrome RFWD3 16q23.1HGNC:25539Ring finger and WD repeat domain 3Fanconi anaemia (FANC‐W) TERF2IP 16q23.1HGNC:19246TERF2 interacting protein POT1 and shelterin‐related tumour predisposition syndrome FANCA 16q24.3HGNC:3582FA complementation group AFanconi anaemia (FANC‐A) Chromosome 17 TP53 17p13.1HGNC:11998Tumour protein p53Li–Fraumeni syndrome FLCN 17p11.2HGNC:27310FolliculinBirt–Hogg–Dube syndrome NF1 17q11.2HGNC:7765Neurofibromin 1Neurofibromatosis type 1; Noonan syndrome RAD51D 17q12HGNC:9823RAD51 paralog D RAD51‐related cancer predisposition syndrome SMARCE1 17q21.2HGNC:11109SWI/SNF related BAF chromatin remodeling complex subunit E1Clear cell meningioma predisposition syndrome BRCA1 17q21.31HGNC:1100BRCA1 DNA repair associated BRCA‐related cancer predisposition syndrome RNF43 17q22HGNC:18505Ring finger protein 43Serrated polyposis RAD51C 17q22HGNC:9820RAD51 paralog C RAD51‐related cancer predisposition syndrome BRIP1 17q23.2HGNC:20473BRCA1 interacting DNA helicase 1Fanconi anaemia (FANC‐J) AXIN2 17q24.1HGNC:904Axin 2 AXIN2‐associated polyposis PRKAR1A 17q24.2HGNC:9388Protein kinase cAMP‐dependent type I regulatory subunit alphaCarney complex GCGR 17q25.3HGNC:4192Glucagon receptorGlucagon cell hyperplasia and neoplasia Chromosome 18 SMAD4 18q21.2HGNC:6770SMAD family member 4Juvenile polyposis syndrome Chromosome 19 STK11 19p13.3HGNC:11389Serine/threonine kinase 11Peutz–Jeghers syndrome SMARCA4 19p13.2HGNC:11100SWI‐/SNF‐related BAF chromatin remodeling complex subunit ATPase 4Rhabdoid tumour predisposition syndrome CEBPA 19q13.11HGNC:1833CCAAT enhancer binding protein alphaHaematolymphoid genetic disorder ERCC2 19q13.32HGNC:3434ERCC excision repair 2, TFIIH core complex helicase subunitXeroderma pigmentosum POLD1 19q13.33HGNC:9175DNA polymerase delta 1, catalytic subunitPolymerase proofreading‐associated polyposis Chromosome 20 GNAS 20q13.32HGNC:4392GNAS complex locusMcCune–Albright syndrome MYT1 20q13.33HGNC:7622Myelin transcription factor 1Goldenhar syndrome Chromosome 21 RUNX1 21q22.12HGNC:10471RUNX family transcription factor 1Haematolymphoid genetic disorder Chromosome 22 DGCR8 22q11.21HGNC:2847DGCR8 microprocessor complex subunitMicroRNA processor tumour predisposition syndromes LZTR1 22q11.21HGNC:6742Leucine zipper like post translational regulator 1Schwannomatosis; Noonan syndrome SMARCB1 22q11.23HGNC:11103SWI/SNF related BAF chromatin remodeling complex subunit B1Schwannomatosis; Rhabdoid tumour predisposition syndrome CHEK2 22q12.1HGNC:16627Checkpoint kinase 2 CHEK2‐related hereditary (breast) cancer predisposition syndrome NF2 22q12.2HGNC:7773NF2, moesin‐ezrin‐radixin like (MERLIN) tumour suppressorNF2‐related schwannomatosis Chromosome X FANCB Xp22.2HGNC:3583FA complementation group BFanconi anaemia (FANC‐B) BTK Xq22.1HGNC:1133Bruton tyrosine kinaseHaematolymphoid genetic disorder DKC1 Xq28HGNC:2890Dyskerin pseudouridine synthase 1Dyskeratosis congenita Tumour susceptibility genes included within the classification are here listed by chromosomal location with their corresponding HGNC gene symbol, ID and gene name. Classification The hierarchical classification for GTS is based on four linked levels: the cellular mechanism (known as the category), the molecular pathway (family), the clinical syndrome and the gene(s) affected with a text description of the most common disease associated changes (Figure 1). The pathway‐based approach adopted addresses the imperfect relationship between genes and tumour predisposition syndromes and emphasises that disruption of specific biological processes underlies neoplasia, with certain pathways or nodes within them recurrently associated with tumour development. Eight broad cellular mechanisms define the highest level categories: growth factor receptors and related pathways; oxidative stress response and metabolism; cell cycle and apoptosis pathways; DNA repair and genomic stability; telomere maintenance; epigenetic drivers and chromatin; RNA regulation and protein regulation. This can be best illustrated by a representative example. Within the category of DNA repair and genomic stability, homologous recombination defines one of the pathways responsible for repair of double‐strand DNA breaks. Pathogenic germline variants in genes including BRCA1, BRCA2, PALB2, RAD51C and RAD51D are grouped within this pathway on the basis of shared biological function. Clinically, these variants define a spectrum of related tumour predisposition syndromes, most prominently hereditary breast and ovarian cancer, with increased risk across multiple tumour types. Although individual genes differ in penetrance and tumour spectrum, their classification within a common pathway reflects shared mechanism and supports convergent clinical strategies, including targeted surveillance and sensitivity to poly ADP‐ribose polymerase (PARP) inhibition. This hierarchical structure unifies multiple genes within a single mechanistic framework while preserving gene‐level specificity. It accommodates overlapping phenotypes and enables incorporation of newly identified genes without redefining the classification. This first edition of the classification of GTS has some limitations that precluded the inclusion of all possible syndromes (Table 2). In some cases, this was because they were extremely rare, while others were not yet sufficiently documented for inclusion. Those syndromes associated with haematolymphoid neoplasms caused considerable discussion. In the end, we opted to include the more common examples and a special introduction to haematolymphoid genetic disorders which will set the scene for future developments. Indeed, it is expected that the classification will evolve (and expand) with future editions. Of those GTS included in this edition, the largest categories were growth factor receptors and their related pathways (38 syndromes), and DNA repair and genomic stability (23 syndromes), while only one protein regulation syndrome was noted—BAP1‐related tumour predisposition syndrome. The classification emphasises certain points, such as the importance of alteration of growth factor receptors and their pathways in predisposition syndromes, while growth factors themselves are not represented. Equally, all DNA repair pathways are represented, with the common syndromes associated with homologous recombination (e.g., BRCA1 and BRCA2) and mismatch repair defects covered in depth. Pathways interact, and the effects of individual gene products on downstream signalling can be complex, producing distinct clinical syndromes despite a shared gene context. For example, variants in APC may result in familial adenomatous polyposis (FAP) or gastric adenocarcinoma and proximal polyposis of stomach (GAPPS) disorders, reflecting differences in the nature and location of the underlying alteration with GAPPS associated with specific promoter variants whereas FAP resulting from loss of function variants throughout the coding region. Conversely, variants within different genes may converge on a common tumour type, as seen in schwannomatosis associated with NF2, SMARCB1 and LZTR1. These relationships illustrate the complexity of genotype–phenotype associations and underscore the value of a pathway‐based framework for organising this diversity. Conclusion The WHO Classification of GTS establishes a unified framework that aligns tumour predisposition with its underlying biological mechanisms. By organising syndromes across linked levels of mechanism, pathway, phenotype and gene, this classification enables integration across disciplines and provides a structure within which new discoveries can be systematically incorporated. The framework also exposes areas of incomplete knowledge, highlighting pathways and syndromes that remain under‐characterised and directing attention towards priorities for future investigation. In doing so, it shifts the classification of tumour predisposition from a descriptive catalogue toward a biologically coherent system. This is not a static taxonomy. It is an infrastructure. As genomic data expand and mechanistic understanding deepens, the value of classification will lie not only in naming disease, but in organising knowledge in a way that predicts, connects and evolves. A mechanism‐based approach is essential to that task, and future iterations will depend on its continued refinement. Classification, in this context, is not an endpoint. It is the foundation on which the next generation of discovery will be built. Author Contributions All authors have accepted responsibility for the entire content of this manuscript and approved its submission. Funding E.A.B. is currently funded by the National Human Genome Research Institute (NHGRI) grant U24HG003345. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Disclosure The content of this article represents the personal views of the authors and does not represent the views of the authors' employers, funders and associated institutions. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Ethics Statement The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.